Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
birelentinib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Phase 3
- Lead developer
- Dizal Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
birelentinib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone is an investigational chemoimmunotherapy regimen combining the novel LYN/BTK dual inhibitor birelentinib (DZD8586) with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Developed by Dizal, this combination is being evaluated as a first-line treatment for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in the Phase 2/3 TAI-SHAN19 trial (NCT07712588). Birelentinib is designed to penetrate the blood-brain barrier and inhibit both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways by targeting LYN and BTK, potentially overcoming resistance mechanisms seen with other BTK inhibitors. The addition of birelentinib to the standard R-CHOP backbone aims to improve efficacy in both germinal center B-cell (GCB) and non-GCB subtypes of DLBCL.
- Other names
- DZD8586 + R-CHOPDZD8586 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisoneDZD8586 plus R-CHOPDZD-8586 plus R-CHOPDZD 8586 plus R-CHOPbirelentinib + R-CHOPbirelentinib plus R-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))BTK (Bruton tyrosine kinase)LYN (LYN proto-oncogene, Src family tyrosine kinase)
Beyond the preview
Go deeper on birelentinib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on birelentinib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.